A multiclinic, placebo-controlled, double-blind study of prostaglandin E1 in Raynaud's syndrome

J. S. Mohrland, J. M. Porter, E. A. Smith, J. Belch, M. H. Simms

    Research output: Contribution to journalArticle

    53 Citations (Scopus)

    Abstract

    Prostaglandin E1 (alprostadil, Prostin VR Sterile Solution, PGE1) was evaluated in patients with Raynaud's syndrome in a multiclinic, placebo-controlled, double-blind study. A total of 55 patients with either primary Raynaud's disease or Raynaud's disease secondary to systemic sclerosis were randomly assigned to receive either PGE1 administered intravenously at 10 ng/kg/min for 72 hours or placebo administered in the same manner. The frequency and severity of Raynaud's attacks were then monitored for up to four weeks by use of in-clinic questionnaires and patients' daily diaries. Haemodynamic assessments included measurements of skin temperature and the finger systolic pressure response to localised digital cooling. Immediately after the infusion the overall symptoms in both the PGE1 and the placebo group showed marked improvement; by four weeks after infusion, in some cases, values had not returned to pretreatment levels. There was, however, no marked benefit of PGE1 treatment over that of placebo. Although PGE1 significantly increased skin temperature during and immediately after infusion, the effect did not persist at two- and four-week follow-up evaluations. The finger systolic pressure response to localised digital cooling (15 degrees C) increased more in the PGE1-treated group than in the placebo-treated group, but the difference was not statistically significant. There was no difference in ulcer healing between the two treatment groups. These results failed to substantiate earlier open-label reports that a 72-hour intravenous infusion of PGE1 in patients with Raynaud's syndrome produced significant clinical benefit.
    Original languageEnglish
    Pages (from-to)754-760
    Number of pages7
    JournalAnnals of the Rheumatic Diseases
    Volume44
    Issue number11
    DOIs
    Publication statusPublished - 1985

    Fingerprint

    Alprostadil
    Double-Blind Method
    Placebos
    Raynaud Disease
    Skin Temperature
    Fingers
    Skin
    Blood Pressure
    Cooling
    Systemic Scleroderma
    Hemodynamics
    Intravenous Infusions
    Ulcer
    Labels
    Temperature

    Cite this

    Mohrland, J. S. ; Porter, J. M. ; Smith, E. A. ; Belch, J. ; Simms, M. H. / A multiclinic, placebo-controlled, double-blind study of prostaglandin E1 in Raynaud's syndrome. In: Annals of the Rheumatic Diseases. 1985 ; Vol. 44, No. 11. pp. 754-760.
    @article{2380796ab6344568880e76bb4e94d96c,
    title = "A multiclinic, placebo-controlled, double-blind study of prostaglandin E1 in Raynaud's syndrome",
    abstract = "Prostaglandin E1 (alprostadil, Prostin VR Sterile Solution, PGE1) was evaluated in patients with Raynaud's syndrome in a multiclinic, placebo-controlled, double-blind study. A total of 55 patients with either primary Raynaud's disease or Raynaud's disease secondary to systemic sclerosis were randomly assigned to receive either PGE1 administered intravenously at 10 ng/kg/min for 72 hours or placebo administered in the same manner. The frequency and severity of Raynaud's attacks were then monitored for up to four weeks by use of in-clinic questionnaires and patients' daily diaries. Haemodynamic assessments included measurements of skin temperature and the finger systolic pressure response to localised digital cooling. Immediately after the infusion the overall symptoms in both the PGE1 and the placebo group showed marked improvement; by four weeks after infusion, in some cases, values had not returned to pretreatment levels. There was, however, no marked benefit of PGE1 treatment over that of placebo. Although PGE1 significantly increased skin temperature during and immediately after infusion, the effect did not persist at two- and four-week follow-up evaluations. The finger systolic pressure response to localised digital cooling (15 degrees C) increased more in the PGE1-treated group than in the placebo-treated group, but the difference was not statistically significant. There was no difference in ulcer healing between the two treatment groups. These results failed to substantiate earlier open-label reports that a 72-hour intravenous infusion of PGE1 in patients with Raynaud's syndrome produced significant clinical benefit.",
    author = "Mohrland, {J. S.} and Porter, {J. M.} and Smith, {E. A.} and J. Belch and Simms, {M. H.}",
    year = "1985",
    doi = "10.1136/ard.44.11.754",
    language = "English",
    volume = "44",
    pages = "754--760",
    journal = "Annals of the Rheumatic Diseases",
    issn = "0003-4967",
    publisher = "BMJ Publishing Group",
    number = "11",

    }

    A multiclinic, placebo-controlled, double-blind study of prostaglandin E1 in Raynaud's syndrome. / Mohrland, J. S.; Porter, J. M.; Smith, E. A.; Belch, J.; Simms, M. H.

    In: Annals of the Rheumatic Diseases, Vol. 44, No. 11, 1985, p. 754-760.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - A multiclinic, placebo-controlled, double-blind study of prostaglandin E1 in Raynaud's syndrome

    AU - Mohrland, J. S.

    AU - Porter, J. M.

    AU - Smith, E. A.

    AU - Belch, J.

    AU - Simms, M. H.

    PY - 1985

    Y1 - 1985

    N2 - Prostaglandin E1 (alprostadil, Prostin VR Sterile Solution, PGE1) was evaluated in patients with Raynaud's syndrome in a multiclinic, placebo-controlled, double-blind study. A total of 55 patients with either primary Raynaud's disease or Raynaud's disease secondary to systemic sclerosis were randomly assigned to receive either PGE1 administered intravenously at 10 ng/kg/min for 72 hours or placebo administered in the same manner. The frequency and severity of Raynaud's attacks were then monitored for up to four weeks by use of in-clinic questionnaires and patients' daily diaries. Haemodynamic assessments included measurements of skin temperature and the finger systolic pressure response to localised digital cooling. Immediately after the infusion the overall symptoms in both the PGE1 and the placebo group showed marked improvement; by four weeks after infusion, in some cases, values had not returned to pretreatment levels. There was, however, no marked benefit of PGE1 treatment over that of placebo. Although PGE1 significantly increased skin temperature during and immediately after infusion, the effect did not persist at two- and four-week follow-up evaluations. The finger systolic pressure response to localised digital cooling (15 degrees C) increased more in the PGE1-treated group than in the placebo-treated group, but the difference was not statistically significant. There was no difference in ulcer healing between the two treatment groups. These results failed to substantiate earlier open-label reports that a 72-hour intravenous infusion of PGE1 in patients with Raynaud's syndrome produced significant clinical benefit.

    AB - Prostaglandin E1 (alprostadil, Prostin VR Sterile Solution, PGE1) was evaluated in patients with Raynaud's syndrome in a multiclinic, placebo-controlled, double-blind study. A total of 55 patients with either primary Raynaud's disease or Raynaud's disease secondary to systemic sclerosis were randomly assigned to receive either PGE1 administered intravenously at 10 ng/kg/min for 72 hours or placebo administered in the same manner. The frequency and severity of Raynaud's attacks were then monitored for up to four weeks by use of in-clinic questionnaires and patients' daily diaries. Haemodynamic assessments included measurements of skin temperature and the finger systolic pressure response to localised digital cooling. Immediately after the infusion the overall symptoms in both the PGE1 and the placebo group showed marked improvement; by four weeks after infusion, in some cases, values had not returned to pretreatment levels. There was, however, no marked benefit of PGE1 treatment over that of placebo. Although PGE1 significantly increased skin temperature during and immediately after infusion, the effect did not persist at two- and four-week follow-up evaluations. The finger systolic pressure response to localised digital cooling (15 degrees C) increased more in the PGE1-treated group than in the placebo-treated group, but the difference was not statistically significant. There was no difference in ulcer healing between the two treatment groups. These results failed to substantiate earlier open-label reports that a 72-hour intravenous infusion of PGE1 in patients with Raynaud's syndrome produced significant clinical benefit.

    U2 - 10.1136/ard.44.11.754

    DO - 10.1136/ard.44.11.754

    M3 - Article

    C2 - 3904643

    VL - 44

    SP - 754

    EP - 760

    JO - Annals of the Rheumatic Diseases

    JF - Annals of the Rheumatic Diseases

    SN - 0003-4967

    IS - 11

    ER -